Global Cancer Supportive Care Drugs Market 2022-2028
According to the Multinational Association for Supportive Care in Cancer, supportive care is the prevention and management of the adverse effects of cancer and its treatment. This includes management of physical and psychological symptoms and side-effects across the continuum of the cancer experience from diagnosis through anticancer treatment to post-treatment care. The market for cancer supportive care drugs worldwide is expected to reach USD 21,913 million by 2028, recording a CAGR of 1.4% over the forecast period as per the latest report by Gen Consulting Company.
The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global cancer supportive care drugs market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the cancer supportive care drugs industry.
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the drug class, and region. The global market for cancer supportive care drugs can be segmented by drug class: antiemetics, bisphosphonates, erythropoiesis-stimulating agents (ESA), granulocyte colony-stimulating factors (G-CSFs), non-steroidal auto inflammatory drugs (NSAIDs), opioids, others. Cancer supportive care drugs market is further segmented by region: North America, Asia Pacific, Europe, Rest of the World (ROW).
By drug class:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook